Product Description
The research-grade biosimilar is a humanized IgG1 kappa monoclonal antibody that acts as an antagonist for IL-5. IL-5 is a major cytokine that plays an important role in the recruitment, activation, growth, differentiation, and survival of eosinophil cells. The antibody binds to IL-5 and inhibits its interaction with the IL-5 receptor, localized on the surface of eosinophil cells. This prevents IL-5 mediated signaling and results in reduced survival of eosinophil cells and reduced inflammation. The original drug received approval from the FDA in 2015 for the treatment of severe eosinophilic asthma.
Biovision | A2158 | Anti-IL5 (Mepolizumab), Humanized Antibody DataSheet
Antibody Target: IL-5
Target Alternative Name: SB 240563, SB-240563, EDF, TRF
Tag Line: The biosimilar is a humanized monoclonal antibody that targets IL-5 and prevents binding of IL-5 with its receptor located on the surface of eosinophil cells, thus reducing inflammation
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Human IL-5
Accession #: DB06612
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE